Guard Therapeutics International AB (DE:5LH0)
FRANKFURT:5LH0
Want to see DE:5LH0 full AI Analyst Report?
5LH0 Stock Chart & Stats
€0.04
€0.06(3.57%)
At close: 4:00 PM EST
€0.04
€0.06(3.57%)
Day’s Range― - ―
52-Week Range€0.01 - €2.27
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.91M
Enterprise Value-€29.09M
Total Cash (Recent Filing)€100.48M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta2.21
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding20,167,631
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA consistent absence of debt reduces refinancing and covenant risk, giving management strategic optionality to prioritize R&D or partnerships without near-term interest obligations. Over a 2–6 month horizon, being debt-free materially lowers forced financing pressure compared with leveraged peers.
Platform R&D Focus (A1M)A platform centered on A1M and kidney disease creates durable scientific optionality: the same biology can support multiple indications or candidate programs, enabling licensing or collaboration strategies. This structural focus supports long-term value creation if clinical progress continues.
Lean Organizational FootprintA small headcount implies a lean cost base and the ability to outsource trials and development activities, which can extend runway per financing round. Over months this helps preserve capital and focus spending on core clinical milestones, improving operational resilience.
Bears Say
No Commercial RevenueSustained zero revenue means the business remains pre-commercial and fully dependent on external funding or partnerships to sustain operations. Over a 2–6 month horizon this elevates execution risk: without clear near-term commercialization or partner deals, funding needs may force dilution or strategic trade-offs.
Persistent Heavy Cash BurnLarge, consistently negative operating and free cash flows are depleting assets rapidly and make the company reliant on new capital or collaborations. This structural cash consumption meaningfully shortens runway and raises the probability of dilutive financings or constrained program choices in the medium term.
Eroding Equity And Asset BaseA sharp decline in equity and total assets reduces the financial cushion available to absorb further losses or fund clinical programs. This weakened balance sheet heightens insolvency and funding risk, limiting flexibility for partnerships or large-scale trials without new capital.
5LH0 FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was €0.01 and its highest was €2.27 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is €1.91M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is May 13, 2026 which is in 12 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on Feb 20, 2026. The company reported -€0.075 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.075.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -€0.075 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in DE:5LH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―